John Leighton, MD, shares the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients at Annual Meeting 2018.
The outcomes of Checkmate 142 in mCRC
John Leighton, MD, shares the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients at Annual Meeting 2018.